151 related articles for article (PubMed ID: 25676034)
1. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Carras S; Regny C; Peoc'h M; Gervasoni J; Gressin R; Cahn JY; Molina L
Leuk Lymphoma; 2015; 56(10):2986-8. PubMed ID: 25676034
[No Abstract] [Full Text] [Related]
2. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
3. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Yanamandra U; Sahu KK; Jain N; Prakash G; Saikia U; Malhotra P
Ann Hematol; 2016 Oct; 95(10):1715-7. PubMed ID: 27324386
[No Abstract] [Full Text] [Related]
4. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
5. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
6. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Cheng L; Song Q; Liu M; Wang Y; Yi H; Qian Y; Xu P; Cheng S; Wang C; Wang L; Zhao W
Front Immunol; 2021; 12():702593. PubMed ID: 34322131
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of lenalidomide in non-Hodgkin lymphoma.
Galanina N; Petrich A; Nabhan C
Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
10. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
11. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review.
Lin L; Zhang X; Dong M; Li L; Wang X; Zhang L; Fu X; Sun Z; Wu J; Li Z; Chang Y; Wang Y; Zhou Z; Zhang M; Chen Q
Medicine (Baltimore); 2017 Feb; 96(7):e6171. PubMed ID: 28207555
[TBL] [Abstract][Full Text] [Related]
14. Solitary plasmablastic lymphoma in the esophagus.
Mihara K; Sasaki N; Mamoru O; Kanbe M; Ichinohe T; Suehiro S
Ann Hematol; 2016 Apr; 95(5):845-6. PubMed ID: 26925582
[No Abstract] [Full Text] [Related]
15. Vulvar and gastric involvement in plasmablastic lymphoma.
Galvão Ferreira PA; Gomes Luna C; Silva MF; Soares LC; Pinho de Oliveira MA
Eur J Gynaecol Oncol; 2017; 38(2):308-310. PubMed ID: 29953802
[TBL] [Abstract][Full Text] [Related]
16. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
17. Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Broccoli A; Pellegrini C; Celli M; Argnani L; Agostinelli C; Pileri S; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e119-22. PubMed ID: 24629851
[No Abstract] [Full Text] [Related]
18. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
van de Donk NW; Wittebol S; Minnema MC; Lokhorst HM
Br J Haematol; 2010 Jan; 148(2):335-7. PubMed ID: 20085583
[No Abstract] [Full Text] [Related]
19. Lenalidomide in CLL: what is the optimal dose?
Wendtner CM
Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
[No Abstract] [Full Text] [Related]
20. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
